Cabaletta Bio to Participate in Upcoming Investor Conferences in September

Rhea-AI Summary

Cabaletta Bio, a clinical-stage biotechnology company focused on targeted cell therapies for autoimmune diseases, announced its participation in two investor conferences in September 2022. CEO Steven Nichtberger will engage in fireside chats at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12 and the H.C. Wainwright 24th Annual Global Investment Conference on September 14, both in New York. Live webcasts will be available on the company's website, with replays accessible for 30 days.

PHILADELPHIA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that the Company will participate in two upcoming investor conferences in September:

• Morgan Stanley 20th Annual Global Healthcare Conference: Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a fireside chat on Monday, September 12, 2022 at 1:05 p.m. ET in New York, NY.

• H.C. Wainwright 24th Annual Global Investment Conference: Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a fireside chat on Wednesday, September 14, 2022 at 9:30 a.m. ET in New York, NY.
  

A live webcast of these presentations will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays will be available on the website for 30 days.

About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform, in combination with Cabaletta Bio’s proprietary technology, has advanced a growing pipeline that currently includes potential treatments for patients with mucosal pemphigus vulgaris, MuSK-associated myasthenia gravis, PLA2R-associated membranous nephropathy, mucocutaneous pemphigus vulgaris and hemophilia A with FVIII alloantibodies. Cabaletta Bio’s headquarters are located in Philadelphia, PA. For more information, visit www.cabalettabio.com and follow us on LinkedIn.

Contacts:

Anup Marda
Chief Financial Officer
investors@cabalettabio.com

Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah.mccabe@sternir.com

FAQ

What conferences will Cabaletta Bio attend in September 2022?

Cabaletta Bio will attend the Morgan Stanley 20th Annual Global Healthcare Conference and the H.C. Wainwright 24th Annual Global Investment Conference.

When is Cabaletta Bio's presentation at the Morgan Stanley Conference?

Cabaletta Bio will present at the Morgan Stanley Conference on September 12, 2022, at 1:05 p.m. ET.

What is the date and time for Cabaletta Bio's presentation at the H.C. Wainwright Conference?

The presentation at the H.C. Wainwright Conference is scheduled for September 14, 2022, at 9:30 a.m. ET.

Who will represent Cabaletta Bio at the investor conferences?

CEO Steven Nichtberger will represent Cabaletta Bio at both investor conferences.

Where can I watch the Cabaletta Bio conference presentations?

The presentations can be viewed live on the News and Events section of Cabaletta Bio's website.